Curaleaf Stock Jumps 6% on Aurora Bid Speculation, Florida Push

Aurora Bid Rumors Resurface as MSO Valuations Compress

The rally came as cannabis industry chatter revived the possibility of Aurora Cannabis making a formal offer for Curaleaf, a deal that would create North America's largest vertically integrated operator. No official bid has been filed. But three industry sources told CannIntel that Aurora's board discussed a cash-and-stock proposal in August. Curaleaf's market cap sits at roughly $2.1 billion, down 48% year-over-year, making it a plausible target for a Canadian LP with cross-border ambitions.

Aurora's been hunting U.S. exposure since federal rescheduling stalled in early 2026. Curaleaf operates 149 dispensaries across 18 states and holds cultivation licenses in Florida, New Jersey, Pennsylvania, and Arizona—four of the five largest medical markets. The synergy thesis is obvious: Aurora's capital access and Curaleaf's retail footprint.

That math is hard to argue with. Yet the deal faces two headwinds: Curaleaf's $680 million debt load and the fact that cross-border M&A remains in regulatory limbo until the DEA finalizes its rescheduling rule. The NPRM public comment period closed in July with no timeline for a final order.

Florida Expansion Accelerates Ahead of Amendment 3 Vote

Curaleaf opened its 38th Florida dispensary in Ocala last week and has four more locations slated to launch before November 5, when voters decide on Amendment 3, the adult-use legalization measure. If the ballot initiative passes with the required 60% supermajority, Florida becomes the third-largest legal cannabis market in the U.S. overnight, behind only California and New York.

Curaleaf has invested $140 million in Florida cultivation and retail infrastructure since 2024, betting that vertical integration will deliver 40% gross margins in an adult-use environment.

The company currently holds five cultivation licenses in Florida with a combined 2.1 million square feet of canopy. That capacity would support roughly $320 million in annual revenue at adult-use pricing, according to a September investor presentation. Trulieve remains the in-state leader with 120 dispensaries, but Curaleaf's aggressive store rollout narrows the gap. All 22 medical marijuana license holders statewide are positioning for adult-use conversion if Amendment 3 passes.

What to Watch: Ballot Math and Debt Refinancing

The next 45 days hinge on two variables: Florida polling and Curaleaf's ability to refinance $230 million in senior notes due in March 2027. The most recent Emerson College poll showed Amendment 3 at 58% support, two points short of the threshold. That's within the margin of error. It also means the outcome is a coin flip.

If Amendment 3 fails, Curaleaf's Florida capex becomes a stranded asset in a medical-only market with flat growth. If it passes, the company's positioned to capture 12-15% market share in a $1.8 billion adult-use market by 2028, according to BDSA projections. Today's 6% pop suggests investors are pricing in a narrow Amendment 3 victory, but that confidence could evaporate quickly if late October polling softens.

On the debt side, Curaleaf has $680 million in total liabilities and generated $63 million in adjusted EBITDA over the last twelve months. It'll need to refinance or extend its 2027 notes, likely at a higher coupon, unless the Aurora deal materializes first. We'll be watching for any 8-K filing on debt restructuring or a formal Aurora LOI before year-end. For full background on Curaleaf's balance sheet and competitive positioning, see the CannIntel topic hub on Curaleaf stock performance.